Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office
June 12 2017 - 6:30AM
Business Wire
– McSwiggen '354 Covers Single-Stranded RNA
Therapeutics Targeting Transthyretin –
– Manoharan '612 Covers RNA Therapeutics of Any
Length with GalNAc Conjugates of Any Valency –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced that the United States Patent
and Trademark Office (USPTO) has issued Notices of Allowance for
two patent applications owned by Alnylam. The USPTO has allowed
claims in patent application 15/483,354, which is a member of the
McSwiggen patent family acquired from Merck in 2014, covering
single-stranded polynucleotides of about 18 to 20 nucleotides
targeting the human transthyretin gene, and comprising 10 or more
phosphorothioate linkages as well as 10 or more chemically modified
pyrimidines. The second allowed patent application, 14/943,612,
which is a member of the Manoharan patent family, contains claims
directed to RNA agents of any length with at least one 2’-O alkyl
modification and 4-20 phosphorothioate linkages conjugated to a
GalNAc moiety of any valency.
“We are pleased with the expansion of our patent portfolio with
these two allowances that significantly enhance our leadership in
intellectual property for RNAi therapeutics,” said Barry Greene,
President of Alnylam. “The McSwiggen ’354 patent complements our
extensive IP portfolio on oligonucleotide-based TTR therapeutics by
extending coverage to single-stranded RNA molecules. The Manoharan
’612 patent broadly covers any GalNAc conjugated, chemically
modified RNA agent of any length and any valency. Together, these
newly allowed patent applications provide yet another layer of
protection for our and our partners’ efforts in bringing innovative
medicines to patients.”
Alnylam’s intellectual property portfolio is comprised of
fundamental, chemistry, delivery and target patents and patent
applications that the company believes are necessary for the
development and commercialization of RNAi therapeutics. In
aggregate, Alnylam owns or has in-licensed over 3,400 active patent
cases, with over 1,400 granted patents world-wide of which over 500
have been granted in the U.S., Europe and Japan. The allowed claims
are available on the Company’s website.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of patients who have
limited or inadequate treatment options. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust discovery platform and deep pipeline of investigational
medicines, including three product candidates that are in
late-stage development or will be in 2017. Looking forward, Alnylam
will continue to execute on its "Alnylam 2020" strategy of building
a multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines. For more information
about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at
@Alnylam.
Alnylam Forward-Looking Statements
Statements in this release concerning Alnylam's future
expectations, plans and prospects, including, without limitation,
statements about Alnylam’s planned continued execution on its
“Alnylam 2020” strategy, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results and future
plans may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, including, without limitation, risks related to
fluctuations in our stock price, those associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed offering, as well as those risks more fully
discussed in the "Risk Factors" filed with Alnylam's most recent
Quarterly Report on Form 10-Q filed with the SEC and in other
filings that Alnylam makes with the SEC. There can be no assurance
that Alnylam will be able to complete the proposed public offering
on the anticipated terms, or at all. You should not place undue
reliance on these forward-looking statements. In addition, any
forward-looking statements represent Alnylam's views only as of
today and should not be relied upon as representing its views as of
any subsequent date. Alnylam explicitly disclaims any obligation,
except to the extent required by law, to update any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170612005534/en/
Alnylam Pharmaceuticals, Inc.Christine Regan Lindenboom,
617-682-4340(Investors and Media)orJosh Brodsky,
617-551-8276(Investors)
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024